Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone?

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week